Discovery of Novel, Potent, and Selective IRAK1 Inhibitors as Potential Therapeutics for Hepatocellular Carcinoma

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Interleukin-1 receptor-associated kinase 1 (IRAK1) is crucial in Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) signaling pathways.
• Aberrant IRAK1 activation is linked to hepatocellular carcinoma (HCC) development.
• Existing IRAK1 inhibitors lack sufficient kinase selectivity, hindering clinical development.

Purpose of the Study:

• To discover and characterize a novel, selective IRAK1 inhibitor.
• To evaluate the anti-cancer potential of the identified inhibitor in HCC models.

Main Methods:

• Structure-based virtual screening and structural optimization were employed to identify IRAK1 inhibitors.
• In vitro kinase inhibition assays were performed to assess potency and selectivity.
• In vivo and in vitro studies were conducted to evaluate anti-HCC activity.

Main Results:

• A novel IRAK1 inhibitor, designated A34, was discovered.
• A34 demonstrated potent inhibition of IRAK1 (IC50 = 10.6 nM) with high selectivity over 215 other kinases, including IRAK4.
• A34 exhibited significant anti-HCC activity in both in vitro and in vivo models.

Conclusions:

• A34 is a potent and highly selective IRAK1 inhibitor.
• A34 serves as a valuable chemical probe for IRAK1 research.
• A34 represents a potential therapeutic lead candidate for hepatocellular carcinoma treatment.